ClinicalTrials.gg
CompletedNCT06974565Updated Jul 25, 2025

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

A Phase 1 interventional study of AZD2389 and Quinidine in Advanced Chronic Liver Disease and Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
9th of 11
16 · median 40
Started
2025
with 3 others
Phase 1
5 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 9th largest by enrollment, is one of 4 that started in 2025, is one of 5 in phase 1, and was the 9th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.

Read the detailed description

This is a 2-way cross-over study to evaluate the effect of quinidine on the PK of AZD2389.

The study will include 2 Treatments - Treatment A - AZD2389 Treatment B - AZD2389 + quinidine

The study will comprise -

  1. A Screening Period of maximum 28 days.
  2. Period 1: single dose administration of Treatment A or Treatment B on Day 1. Period 2 will start after a washout period of at least 7 days.
  3. Period 2: single dose of alternate treatment on Day 8.
  4. A Follow-up Visit: participants will return for a Follow-up Visit, 7 to 14 days after the last AZD2389 PK sample in Period 2.

Participants will be randomized to one of the 2 treatment sequences -

  1. Sequence AB: Treatment A in Period 1, Treatment B in Period 2.
  2. Sequence BA: Treatment B in Period 1, Treatment A in Period 2.
03

Conditions studied

  • Advanced Chronic Liver Disease
  • Healthy Participants

Browse trials for

Keywords

  • Hepatic Fibrosis
  • Fibroblast Activation Protein Inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female (of non-) participants with suitable veins for cannulation or repeated venipuncture.
  • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of non-childbearing potential must be confirmed at the Screening Visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific methods from the time of first administration of study intervention administration until 3 months after the study Follow-up Visit.
  • Have a between 18 and 32 kg/m2, inclusive, and weigh at least 50 kg at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important abnormalities in hematology, clinical chemistry, urinalysis, coagulation results or other laboratory values and vital signs.
  • Any positive result on Screening for serum surface antigen (HBsAg), hepatitis B core antibody (HBcAb), virus antibody (HCV Ab), or (HIV).
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead (ECG) at Screening.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • Current smokers or those who have smoked or used nicotine products within the previous 3 months prior to screening.
  • Positive screen for drugs of abuse, or alcohol or cotinine at Screening.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • History of hypersensitivity to dipeptidyl peptidase 4 (DPP4) inhibitors.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Sequence AB

    Participants will receive a single dose of Treatment A (AZD2389) in Period 1 and a single dose of Treatment B (AZD2389 + quinidine) in Period 2.

    Drug: AZD2389 · Drug: Quinidine

  • Experimental
    Sequence BA

    Participants will receive a single dose of Treatment B (AZD2389 + quinidine) in Period 1 and a single dose of Treatment A (AZD2389) in Period 2.

    Drug: AZD2389 · Drug: Quinidine

Interventions

  • AZD2389 will be administered orally.

  • Quinidine will be administered orally.

06

What researchers measure

Primary outcomes

  1. Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on maximum observed plasma concentration (RCmax)

    To assess the effect of quinidine on the PK of AZD2389.

    Time frame: Day 1 to Day 10

  2. Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on area under concentration-time curve from time 0 to infinity (RAUCinf)

    To assess the effect of quinidine on the PK of AZD2389.

    Time frame: Day 1 to Day 10

  3. Ratio of Test treatment (AZD2389 + quinidine) to Reference treatment (AZD2389) based on area under concentration-time curve from time 0 to the last quantifiable concentration (RAUClast)

    To assess the effect of quinidine on the PK of AZD2389.

    Time frame: Day 1 to Day 10

Secondary outcomes

  1. Apparent total body clearance (CL/F) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  2. Volume of distribution (apparent) following extravascular administration (based on terminal phase) (Vz/F) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  3. Terminal elimination half-life (t1/2λz) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  4. Time to reach maximum observed concentration (tmax) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  5. Maximum observed plasma concentration (Cmax) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  6. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  7. Area under concentration-time curve from time zero to infinity (AUCinf) of AZD2389

    To assess the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  8. Renal Clearance (CLR) of AZD2389 from plasma

    To assess the urine PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  9. Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe[t1-t2]) of AZD2389

    To assess the urine PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  10. Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae[t1-t2]) of AZD2389

    To assess the urine PK of AZD2389 when AZD2389 is administered alone or in combination with quinidine.

    Time frame: Day 1 to Day 10

  11. Percent change from baseline in fibroblast activation protein (FAP) inhibition

    To assess the pharmacodynamics (PD) of AZD2389 by assessment of inhibition of FAP activity in plasma after single oral dose of AZD2389 alone or in combination with quinidine.

    Time frame: Baseline, Day 1 to Day 10

  12. Number of participants with Adverse Events (AEs)

    To assess the safety and tolerability of a single oral dose of AZD2389 alone or in combination with quinidine in healthy participants.

    Time frame: From Screening (Day -28 to Day -2) to Follow-up visit (upto 8 weeks)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2025, 2 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
May 12, 2025
Primary completionActual
Jul 18, 2025
CompletionActual
Jul 18, 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974565
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 12, 2025
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025
Last update
Jul 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion